{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T07:02:31Z","timestamp":1779951751813,"version":"3.53.1"},"reference-count":69,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T00:00:00Z","timestamp":1779926400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Thoracic and head and neck NUT carcinoma is a rare, highly aggressive NUTM1-rearranged malignancy with substantial diagnostic difficulty, marked phenotypic heterogeneity, and no established biomarker framework for immunotherapy stratification. Although fusion partners may contribute to clinicopathologic diversity, their relationship to phenotype and immune biomarkers remains insufficiently defined.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>We performed an integrated literature-based analysis of thoracic and head and neck NUT carcinoma using English-language publications indexed in the Web of Science Core Collection from 1991 to 2025. Eligible studies were screened for clinicopathologic, fusion, and immune-biomarker data. Case-level variables were harmonized into anatomic and lineage-based strata to evaluate associations between fusion partners, phenotype, and immune features. PD-L1 status was harmonized into three descriptive categories based on author interpretation and\/or reported TPS\/CPS thresholds, and a binary sensitivity framework, Negative versus Any expression, was additionally applied to reduce the impact of heterogeneous assays and scoring systems. MSI and TMB were also extracted when available. Associations were assessed using two-sided Fisher\u2019s exact test with odds ratios and 95% confidence intervals. To strengthen the robustness and translational relevance of the findings, we additionally analyzed an independent retrospective institutional cohort of thoracic and head and neck NUT carcinoma.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The integrated clinicopathologic dataset included 229 thoracic\/head and neck cases with definitive fusion annotations from 109 studies. Squamous lineage predominated (71.62%), but non-squamous and mixed phenotypes were also identified.\n                      <jats:italic>BRD4::NUTM1<\/jats:italic>\n                      was significantly enriched in squamous lineage and thoracic squamous subsets, whereas\n                      <jats:italic>YAP1::NUTM1<\/jats:italic>\n                      and\n                      <jats:italic>MGA::NUTM1<\/jats:italic>\n                      were preferentially associated with non-squamous phenotypes and specific strata. In the immune-biomarker subset, PD-L1 was predominantly negative (76.92%), with high expression being uncommon (6.41%). Thoracic squamous tumors showed significant enrichment for PD-L1 negativity. Among cases with both fusion and PD-L1 data, a binary sensitivity analysis confirmed that PD-L1 negativity predominated across fusion-defined subsets, with no significant association between fusion partner and PD-L1 status. Across reported MSI\/TMB cases, tumors were uniformly MSS and generally low in TMB. An independent institutional cohort of 59 patients partially corroborated the major literature-derived signals, particularly\n                      <jats:italic>BRD4::NUTM1<\/jats:italic>\n                      predominance among fusion-annotated cases and PD-L1 negativity among tested tumors, with no significant difference from the literature-derived pooled estimates.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study defines the immune biomarker landscape of thoracic and head and neck NUT carcinoma within a clinicopathologic and fusion-partner framework. The predominance of PD-L1 negativity together with MSS\/low-TMB features suggests a generally immunologically \u201ccold\u201d phenotype in most reported tumors, while exploratory fusion partner\u2013specific enrichment patterns may help refine diagnostic suspicion and generate hypotheses for future biomarker-guided stratification. These findings provide a translational basis for rare-cancer immunobiology research and for the rational design of biomarker-integrated prospective studies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1834366","type":"journal-article","created":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T06:17:04Z","timestamp":1779949024000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Immune biomarker landscape and fusion partner\u2013phenotype associations in thoracic and head-and-neck NUT carcinoma"],"prefix":"10.3389","volume":"17","author":[{"given":"Shuang","family":"Xiang","sequence":"first","affiliation":[{"name":"Medical Pathology Center (MPC), Chongqing University Three Gorges Hospital, Chongqing University","place":["Wanzhou, Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuomiao","family":"Ye","sequence":"additional","affiliation":[{"name":"Clinical Research Center (CRC), Chongqing University Three Gorges Hospital, Chongqing University","place":["Wanzhou, Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifan","family":"Dai","sequence":"additional","affiliation":[{"name":"Chongqing University Three Gorges Hospital and Academy for Advanced Interdisciplinary Technology, CQU-Ferenc Krausz Nobel Laureate Scientific Workstation","place":["Wanzhou, Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shipeng","family":"Shang","sequence":"additional","affiliation":[{"name":"Medical Pathology Center (MPC), Chongqing University Three Gorges Hospital, Chongqing University","place":["Wanzhou, Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Yang","sequence":"additional","affiliation":[{"name":"Cancer Early Detection and Treatment Center (CEDTC), Chongqing University Three Gorges Hospital, Chongqing University","place":["Wanzhou, Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Cheng","sequence":"additional","affiliation":[{"name":"Chongqing University Three Gorges Hospital and Academy for Advanced Interdisciplinary Technology, CQU-Ferenc Krausz Nobel Laureate Scientific Workstation","place":["Wanzhou, Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Deng","sequence":"additional","affiliation":[{"name":"Department of Breast Surgery, Chongqing University Three Gorges Hospital, Chongqing University","place":["Wanzhou, Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minghui","family":"Zhang","sequence":"additional","affiliation":[{"name":"Clinical Research Center (CRC), Chongqing University Three Gorges Hospital, Chongqing University","place":["Wanzhou, Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingzhu","family":"Yin","sequence":"additional","affiliation":[{"name":"Medical Pathology Center (MPC), Chongqing University Three Gorges Hospital, Chongqing University","place":["Wanzhou, Chongqing, China"]},{"name":"Clinical Research Center (CRC), Chongqing University Three Gorges Hospital, Chongqing University","place":["Wanzhou, Chongqing, China"]},{"name":"Chongqing University Three Gorges Hospital and Academy for Advanced Interdisciplinary Technology, CQU-Ferenc Krausz Nobel Laureate Scientific Workstation","place":["Wanzhou, Chongqing, China"]},{"name":"Cancer Early Detection and Treatment Center (CEDTC), Chongqing University Three Gorges Hospital, Chongqing University","place":["Wanzhou, Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1097\/00043426-199124000-00011","article-title":"Intrathoracic carcinoma in an 11-year-old girl showing a translocation t(15;19)","volume":"13","author":"Kees","year":"1991","journal-title":"Am J Pediatr Hematol Oncol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0000000000000630","article-title":"The 2015 World Health Organization classification of lung tumors: Impact of genetic, clinical and radiologic advances since the 2004 classification","volume":"10","author":"Travis","year":"2015","journal-title":"J Thorac Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol28060381","article-title":"NUTM1-rearranged neoplasms-a heterogeneous group of primitive tumors with expanding spectrum of histology and molecular alterations-an updated review","volume":"28","author":"Luo","year":"2021","journal-title":"Curr Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-025-00986-3","article-title":"Hiding in plain sight: NUT carcinoma is an unrecognized subtype of squamous cell carcinoma of the lungs and head and neck","volume":"22","author":"Luo","year":"2025","journal-title":"Nat Rev Clin Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.36922\/td.4904","article-title":"Expert consensus and current landscape of NUT carcinoma: A comprehensive strategy from diagnosis to treatment","volume":"3","author":"Ye","year":"2024","journal-title":"Tumor Discov"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0b013e318198d666","article-title":"Diagnosis of NUT midline carcinoma using a NUT-specific monoclonal antibody","volume":"33","author":"Haack","year":"2009","journal-title":"Am J Surg Pathol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-25-1071","article-title":"Molecular characterization of NUT carcinoma: A report from the NUT carcinoma registry","volume":"31","author":"Kim","year":"2025","journal-title":"Clin Cancer Res"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2023.12.022","article-title":"Initial chemotherapy for locally advanced and metastatic NUT carcinoma","volume":"19","author":"Luo","year":"2024","journal-title":"J Thorac Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtocrr.2025.100885","article-title":"Complete response to BET inhibitor in primary pulmonary NUT carcinoma with single-cell sequencing-based analysis: A case report","volume":"6","author":"Ye","year":"2025","journal-title":"JTO Clin Res Rep"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1002\/hed.70119","article-title":"Radiotherapy outcomes and prognostic factors in head and neck NUT carcinoma: A single-center cohort analysis","volume":"48","author":"Ye","year":"2026","journal-title":"Head Neck"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9440(10)63049-0","article-title":"BRD4 bromodomain gene rearrangement in aggressive carcinoma with translocation t(15;19)","volume":"159","author":"French","year":"2001","journal-title":"Am J Pathol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1097\/JS9.0000000000004432","article-title":"Clinical treatment, research topic and global trends of Kaposiform hemangioendothelioma: a review and bibliometric analysis","author":"Huang","year":"2025","journal-title":"Int J Surg"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1097\/JS9.0000000000003912","article-title":"Epigenetic regulation of varicella-zoster virus infection: a systematic synthesis of mechanisms","volume":"112","author":"Peng","year":"2026","journal-title":"Int J Surg"},{"key":"B14","article-title":"Assessing the risk of bias of individual studies in systematic reviews of health care interventions","volume-title":"Methods guide for effectiveness and comparative effectiveness reviews","author":"Viswanathan","year":"2008"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1300\/j105v01n03_06","article-title":"Sources of information on specific subjects","volume":"137","author":"Bradford","year":"1934","journal-title":"Engineering"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1210852","article-title":"BRD-NUT oncoproteins: a family of closely related nuclear proteins that block epithelial differentiation and maintain the growth of carcinoma cells","volume":"27","author":"French","year":"2008","journal-title":"Oncogene"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.02.107","article-title":"Midline carcinoma of children and young adults with NUT rearrangement","volume":"22","author":"French","year":"2004","journal-title":"J Clin Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-12-1153","article-title":"Clinicopathologic features and long-term outcomes of NUT midline carcinoma","volume":"18","author":"Bauer","year":"2012","journal-title":"Clin Cancer Res"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol29100536","article-title":"Diagnosis, treatment and prognosis of primary pulmonary NUT carcinoma: A literature review","volume":"29","author":"Yuan","year":"2022","journal-title":"Curr Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/emboj.2010.176","article-title":"Oncogenesis by sequestration of CBP\/p300 in transcriptionally inactive hyperacetylated chromatin domains","volume":"29","author":"Reynoird","year":"2010","journal-title":"EMBO J"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-13-2658","article-title":"Activation of SOX2 expression by BRD4-NUT oncogenic fusion drives neoplastic transformation in NUT midline carcinoma","volume":"74","author":"Wang","year":"2014","journal-title":"Cancer Res"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-020-01625-0","article-title":"Supercharging BRD4 with NUT in carcinoma","volume":"40","author":"Eagen","year":"2021","journal-title":"Oncogene"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14092234","article-title":"NUT is a driver of p300-mediated histone hyperacetylation: From spermatogenesis to cancer","volume":"14","author":"Rousseaux","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B24","doi-asserted-by":"publisher","first-page":"11907","DOI":"10.1038\/s41598-023-39102-9","article-title":"Molecular features driving condensate formation and gene expression by the BRD4-NUT fusion oncoprotein are overlapping but distinct","volume":"13","author":"Kosno","year":"2023","journal-title":"Sci Rep"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1101\/gad.267583.115","article-title":"The oncogenic BRD4-NUT chromatin regulator drives aberrant transcription within large topological domains","volume":"29","author":"Alekseyenko","year":"2015","journal-title":"Genes Dev"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1158\/1541-7786.MCR-18-0474","article-title":"\"Z4\" complex member fusions in NUT carcinoma: Implications for a novel oncogenic mechanism","volume":"16","author":"Shiota","year":"2018","journal-title":"Mol Cancer Res"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.26508\/lsa.202402602","article-title":"Brd4::Nutm1 fusion gene initiates NUT carcinoma in vivo","volume":"7","author":"Zheng","year":"2024","journal-title":"Life Sci Alliance"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1136\/jmg.2004.029686","article-title":"Cloned fusion product from a rare t(15;19)(q13.2;p13.1) inhibit S phase in vitro","volume":"42","author":"Haruki","year":"2005","journal-title":"J Med Genet"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.2910500216","article-title":"Establishment and characterization of a thymic carcinoma cell line (Ty-82) carrying t(15;19)(q15;p13) chromosome abnormality","volume":"50","author":"Kuzume","year":"1992","journal-title":"Int J Cancer"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1097\/01.COC.0000020960.98562.84","article-title":"Translocation (11;15;19): a highly specific chromosome rearrangement associated with poorly differentiated thymic carcinoma in young patients","volume":"26","author":"Toretsky","year":"2003","journal-title":"Am J Clin Oncol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-23-2545","article-title":"The BRD4-NUT fusion alone drives malignant transformation of NUT carcinoma","volume":"83","author":"Durall","year":"2023","journal-title":"Cancer Res"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1038\/nature08397","article-title":"Cooperative binding of two acetylation marks on a histone tail by a single bromodomain","volume":"461","author":"Moriniere","year":"2009","journal-title":"Nature"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2018.08.069","article-title":"Nut directs p300-dependent, genome-wide H4 hyperacetylation in male germ cells","volume":"24","author":"Shiota","year":"2018","journal-title":"Cell Rep"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.oraloncology.2025.107185","article-title":"A single-cell sequencing-based analysis of a 13-year-old with maxillary sinus NUT carcinoma","volume":"162","author":"Ye","year":"2025","journal-title":"Oral Oncol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1002\/hed.28231","article-title":"Magnifying glass on sinonasal NUT carcinoma heterogeneity via spatial transcriptomics","volume":"48","author":"Bell","year":"2026","journal-title":"Head Neck"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1101\/2025.02.07.637147","article-title":"Acetylation of histone H2B on lysine 120 regulates BRD4 binding to intergenic enhancers","author":"Hamilton","year":"2025","journal-title":"bioRxiv"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1039\/d5ay00721f","article-title":"High-throughput plasma\/serum proteomics by coupling nanoparticle protein corona-based sample preparation and capillary zone electrophoresis-tandem mass spectrometry","volume":"17","author":"Wang","year":"2025","journal-title":"Anal Methods"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1021\/acschembio.3c00427","article-title":"Development of potent dual BET\/HDAC inhibitors via pharmacophore merging and structure-guided optimization","volume":"19","author":"Bauer","year":"2024","journal-title":"ACS Chem Biol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2025-013539","article-title":"Shared PRAME epitopes are T-cell targets in NUT carcinoma","volume":"14","author":"Jensen","year":"2026","journal-title":"J Immunother Cancer"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2025.108449","article-title":"NUT carcinoma in children and adolescents: An analysis of the European Cooperative Study Group on pediatric rare tumors (EXPeRT)","volume":"201","author":"Flaadt","year":"2025","journal-title":"Lung Cancer"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2024.107496","article-title":"Clinical management of NUT carcinoma (NC) in Germany: Analysis of survival, therapy response, tumor markers and tumor genome sequencing in 35 adult patients","volume":"189","author":"Kloker","year":"2024","journal-title":"Lung Cancer"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1111\/his.15204","article-title":"The histological spectrum and immunoprofile of head and neck NUT carcinoma: A multicentre series of 30 cases","volume":"85","author":"Viswanathan","year":"2024","journal-title":"Histopathology"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1093\/jncics\/pkz094","article-title":"An anatomical site and genetic-based prognostic model for patients with nuclear protein in testis (NUT) midline carcinoma: Analysis of 124 patients","volume":"4","author":"Chau","year":"2020","journal-title":"JNCI Cancer Spectr"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2025.104499","article-title":"Final results from the phase Ia\/Ib study of the novel bromodomain and extra-terminal domain inhibitor, BI 894999, in patients with advanced solid tumors or diffuse large B-cell lymphoma","volume":"10","author":"Lauer","year":"2025","journal-title":"ESMO Open"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-022-01815-5","article-title":"Therapeutic impact of BET inhibitor BI 894999 treatment: backtranslation from the clinic","volume":"127","author":"Tontsch-Grunt","year":"2022","journal-title":"Br J Cancer"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1007\/s12105-020-01130-6","article-title":"HDAC overexpression in a NUT midline carcinoma of the parotid gland with exceptional survival: A case report","volume":"14","author":"Esteves","year":"2020","journal-title":"Head Neck Pathol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1093\/jncics\/pkz093","article-title":"Phase 1 study of Molibresib (GSK525762), a bromodomain and extra-terminal domain protein inhibitor, in NUT carcinoma and other solid tumors","volume":"4","author":"Piha-Paul","year":"2020","journal-title":"JNCI Cancer Spectr"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-020-01180-1","article-title":"A phase 1 study of RO6870810, a novel bromodomain and extra-terminal protein inhibitor, in patients with NUT carcinoma, other solid tumours, or diffuse large B-cell lymphoma","volume":"124","author":"Shapiro","year":"2021","journal-title":"Br J Cancer"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.78.2292","article-title":"Phase Ib trial with Birabresib, a small-molecule inhibitor of bromodomain and extraterminal proteins, in patients with selected advanced solid tumors","volume":"36","author":"Lewin","year":"2018","journal-title":"J Clin Oncol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2020.10.016","article-title":"Prolonged disease control on Nivolumab for primary pulmonary NUT carcinoma","volume":"22","author":"Davis","year":"2021","journal-title":"Clin Lung Cancer"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.4143\/crt.2022.910","article-title":"Cancer-specific sequences in the diagnosis and treatment of NUT carcinoma","volume":"55","author":"Lee","year":"2023","journal-title":"Cancer Res Treat"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2022.03.001","article-title":"Primary pulmonary NUT carcinoma: Case illustration and updated review of literature","volume":"23","author":"Costa","year":"2022","journal-title":"Clin Lung Cancer"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1002\/dc.24885","article-title":"BRD3-NUTM1-expressing NUT carcinoma of lung on endobronchial ultrasound-guided transbronchial needle aspiration cytology, a diagnostic pitfall","volume":"50","author":"Aryal","year":"2022","journal-title":"Diagn Cytopathol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.995744","article-title":"Case report: Immunovirotherapy as a novel add-on treatment in a patient with thoracic NUT carcinoma","volume":"12","author":"Kloker","year":"2022","journal-title":"Front Oncol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.13648","article-title":"Clinicopathological characteristics of primary lung nuclear protein in testis carcinoma: A single-institute experience of 10 cases","volume":"11","author":"Cho","year":"2020","journal-title":"Thorac Cancer"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.30821","article-title":"NUT carcinoma in pediatric patients: Characteristics, therapeutic regimens, and outcomes of 11 cases registered with the German Registry for Rare Pediatric Tumors (STEP)","volume":"71","author":"Flaadt","year":"2024","journal-title":"Pediatr Blood Cancer"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1016\/j.canrad.2024.02.004","article-title":"Nuclear protein in testis (NUT) midline carcinoma of the larynx: A rare case report of a paediatric patient and literature review","volume":"28","author":"Ugurluer","year":"2024","journal-title":"Cancer Radiother"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1210\/jcemcr\/luae037","article-title":"A rare case of NUT carcinoma of the thyroid","volume":"2","author":"Cadesky","year":"2024","journal-title":"JCEM Case Rep"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.21037\/gs-24-77","article-title":"Primary thyroid nuclear protein in testis carcinoma: a case report and literature review","volume":"13","author":"Cao","year":"2024","journal-title":"Gland Surg"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.36401\/JIPO-23-19","article-title":"Sustained clinical response to immunotherapy followed by BET inhibitor in a patient with unresectable sinonasal NUT carcinoma","volume":"7","author":"Herbison","year":"2024","journal-title":"J Immunother Precis Oncol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.778296","article-title":"Primary thyroid NUT carcinoma with high PD-L1 expression and novel massive IGKV gene fusions: A case report with treatment implications and literature review","volume":"11","author":"Zhou","year":"2021","journal-title":"Front Oncol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1094770","article-title":"The whole treatment process and thinking of a patient with NUT carcinoma of the parotid gland: a case report","volume":"13","author":"Fu","year":"2023","journal-title":"Front Oncol"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2021.101184","article-title":"Genomic profiling of solid tumors harboring BRD4-NUT and response to immune checkpoint inhibitors","volume":"14","author":"Riess","year":"2021","journal-title":"Transl Oncol"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1497124","article-title":"Pulmonary NUT carcinoma, an elusive and refractory entity, shows transient response to chemotherapeutics and PD-1 inhibitor: a case report and literature review","volume":"16","author":"Yang","year":"2025","journal-title":"Front Immunol"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.4103\/jcrt.jcrt_1083_22","article-title":"Immunotherapy experience in sinonasal NUT midline carcinoma, case report","volume":"20","author":"Caner","year":"2024","journal-title":"J Cancer Res Ther"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1097\/MS9.0000000000001501","article-title":"Suspected NUT carcinoma progressing on pembrolizumab, carboplatin, and paclitaxel as first-line treatment: a case report","volume":"86","author":"Badran","year":"2024","journal-title":"Ann Med Surg (Lond)"},{"key":"B67","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1038\/s41698-024-00768-7","article-title":"Adding checkpoint inhibitors to first-line chemotherapy for NUT carcinoma patients","volume":"9","author":"Haebe","year":"2025","journal-title":"NPJ Precis Oncol"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-023-04621-5","article-title":"Clinical and molecular features of pulmonary NUT carcinoma characterizes diverse responses to immunotherapy, with a pathologic complete response case","volume":"149","author":"Chen","year":"2023","journal-title":"J Cancer Res Clin Oncol"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2023-259538","article-title":"Placental metastasis from maternal NUT carcinoma: diagnostic pitfalls and challenges","volume":"17","author":"Lai","year":"2024","journal-title":"BMJ Case Rep"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1834366\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T06:17:07Z","timestamp":1779949027000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1834366\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,28]]},"references-count":69,"alternative-id":["10.3389\/fimmu.2026.1834366"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1834366","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,28]]},"article-number":"1834366"}}